Hui-Ling Zou1, Yan Wang2, Qiang Gang1, Ying Zhang1, Yu Sun3. 1. Department of Endocrinology and Metabolism, Suqian People's Hospital, Nanjing Drum Tower Hospital, No. 138, South Yellow River Road, Suqian, 223800, Jiangsu Province, People's Republic of China. 2. Department of Geriatrics, Suqian People's Hospital, Nanjing Drum Tower Hospital, Suqian, 223800, People's Republic of China. 3. Department of Endocrinology and Metabolism, Suqian People's Hospital, Nanjing Drum Tower Hospital, No. 138, South Yellow River Road, Suqian, 223800, Jiangsu Province, People's Republic of China. sqsunyu@126.com.
Abstract
PURPOSE: MicroRNA-93 (miR-93) usually acts as a promoter of tumor progression in several human carcinomas. It has been found distinctly high in eyes with proliferative diabetic retinopathy (DR). The present study aims to investigate the role of plasma miR-93 in the progression of type 2 diabetic retinopathy (T2DR). METHODS: Our study subjects were made up of 140 type 2 diabetes mellitus (T2DM) patients who were assigned into DR (DR patients, n = 75), NDR (non-DR patients, n = 65), and control (healthy individuals, n = 127) groups. Levels of fasting blood glucose (FBG), fasting plasma glucose (FPG), triglyceride (TG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), blood urea nitrogen (BUN), creatinine (Cr), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and fasting insulin (FIsn) were detected by automatic biochemical analyzer. Enzyme-linked immunosorbent assay (ELISA) was performed for the levels of interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α and vascular endothelial growth factor (VEGF), qRT-PCR for the miR-93 expression in plasma, and mRNA expressions of IL-1, IL-6, TNF-α and VEGF; receiver operating characteristic (ROC) curve for the diagnostic performance of miR-93 to T2DR, Pearson correlation analysis for correlation analysis between miR-93 and other indexes detected before and multivariate logistic regression analyses for the risk factors for T2DR. RESULTS: The DR and NDR groups exhibited elevated course of disease, and decreased levels of FBG, FPG, TG, HbA1c, TC, BUN, Cr, HDL-C, FIsn, IL-1, IL-6, TNF-α and VEGF but declined LDL-C level as compared to the control group. The course of disease was longer and the levels of FBG, FPG, HbA1c, IL1, IL6 and VEGF were higher in the DR group than those in the NDR group (all P < 0.05). The miR-93 expression and RNA expressions of IL-1, IL-6, TNF-α and VEGF were higher in the DR group than those in the NDR group (P < 0.05). The best cutoff for miR-93 to assess T2DR was 1.31, with a Youden index of 0.63, sensitivity of 73.33%, specificity of 89.24%, and area under the curve (AUC) of 0.866. Pearson correlation analysis indicated that miR-93 expression was positively associated with course of disease, the levels of FPG, HbA1c, TNF-α and VEGF. T2DM patients with longer disease course, higher levels of FBG, HbA1c, VEGF and miR-93 expression were risk factors for developing DR. CONCLUSION: Our study demonstrates that plasma miR-93 is associated with the progression of T2DR and it can sever as a diagnostic marker for T2DR.
PURPOSE:MicroRNA-93 (miR-93) usually acts as a promoter of tumor progression in several humancarcinomas. It has been found distinctly high in eyes with proliferative diabetic retinopathy (DR). The present study aims to investigate the role of plasma miR-93 in the progression of type 2 diabetic retinopathy (T2DR). METHODS: Our study subjects were made up of 140 type 2 diabetes mellitus (T2DM) patients who were assigned into DR (DR patients, n = 75), NDR (non-DR patients, n = 65), and control (healthy individuals, n = 127) groups. Levels of fasting blood glucose (FBG), fasting plasma glucose (FPG), triglyceride (TG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), blood ureanitrogen (BUN), creatinine (Cr), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and fasting insulin (FIsn) were detected by automatic biochemical analyzer. Enzyme-linked immunosorbent assay (ELISA) was performed for the levels of interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α and vascular endothelial growth factor (VEGF), qRT-PCR for the miR-93 expression in plasma, and mRNA expressions of IL-1, IL-6, TNF-α and VEGF; receiver operating characteristic (ROC) curve for the diagnostic performance of miR-93 to T2DR, Pearson correlation analysis for correlation analysis between miR-93 and other indexes detected before and multivariate logistic regression analyses for the risk factors for T2DR. RESULTS: The DR and NDR groups exhibited elevated course of disease, and decreased levels of FBG, FPG, TG, HbA1c, TC, BUN, Cr, HDL-C, FIsn, IL-1, IL-6, TNF-α and VEGF but declined LDL-C level as compared to the control group. The course of disease was longer and the levels of FBG, FPG, HbA1c, IL1, IL6 and VEGF were higher in the DR group than those in the NDR group (all P < 0.05). The miR-93 expression and RNA expressions of IL-1, IL-6, TNF-α and VEGF were higher in the DR group than those in the NDR group (P < 0.05). The best cutoff for miR-93 to assess T2DR was 1.31, with a Youden index of 0.63, sensitivity of 73.33%, specificity of 89.24%, and area under the curve (AUC) of 0.866. Pearson correlation analysis indicated that miR-93 expression was positively associated with course of disease, the levels of FPG, HbA1c, TNF-α and VEGF. T2DM patients with longer disease course, higher levels of FBG, HbA1c, VEGF and miR-93 expression were risk factors for developing DR. CONCLUSION: Our study demonstrates that plasma miR-93 is associated with the progression of T2DR and it can sever as a diagnostic marker for T2DR.
Entities:
Keywords:
Diagnosis; MicroRNA-93; Sensitivity; Specificity; Type 2 diabetes mellitus; Type 2 diabetic retinopathy
Authors: Kathryn P Burdon; Rhys D Fogarty; Weiyong Shen; Sotoodeh Abhary; Georgia Kaidonis; Binoy Appukuttan; Alex W Hewitt; Shiwani Sharma; Mark Daniell; Rohan W Essex; John H Chang; Sonja Klebe; Stewart R Lake; Bishwanath Pal; Alicia Jenkins; Gowthaman Govindarjan; Periasamy Sundaresan; Ecosse L Lamoureux; Kim Ramasamy; Maria Pefkianaki; Philip G Hykin; Nikolai Petrovsky; Matthew A Brown; Mark C Gillies; Jamie E Craig Journal: Diabetologia Date: 2015-07-19 Impact factor: 10.122
Authors: B M Herrera; H E Lockstone; J M Taylor; M Ria; A Barrett; S Collins; P Kaisaki; K Argoud; C Fernandez; M E Travers; J P Grew; J C Randall; A L Gloyn; D Gauguier; M I McCarthy; C M Lindgren Journal: Diabetologia Date: 2010-03-03 Impact factor: 10.122
Authors: Yiling J Cheng; Edward W Gregg; Linda S Geiss; Giuseppina Imperatore; Desmond E Williams; Xinzhi Zhang; Ann L Albright; Catherine C Cowie; Ronald Klein; Jinan B Saaddine Journal: Diabetes Care Date: 2009-11 Impact factor: 17.152
Authors: Ling Fang; William W Du; Weining Yang; Zina Jeyapalan Rutnam; Chun Peng; Haoran Li; Yunxia Q O'Malley; Ryan W Askeland; Sonia Sugg; Mingyao Liu; Tanvi Mehta; Zhaoqun Deng; Burton B Yang Journal: Cell Cycle Date: 2012-10-30 Impact factor: 4.534
Authors: Maria Enoia Dantas da Costa E Silva; Evelise Regina Polina; Daisy Crispim; Renan Cesar Sbruzzi; Daniel Lavinsky; Felipe Mallmann; Nidiane Carla Martinelli; Luis Henrique Canani; Katia Gonçalves Dos Santos Journal: J Cell Mol Med Date: 2018-11-23 Impact factor: 5.310
Authors: Marta Greco; Eusebio Chiefari; Francesca Accattato; Domenica M Corigliano; Biagio Arcidiacono; Maria Mirabelli; Rossella Liguori; Francesco S Brunetti; Salvatore A Pullano; Vincenzo Scorcia; Antonino S Fiorillo; Daniela P Foti; Antonio Brunetti Journal: Front Endocrinol (Lausanne) Date: 2020-08-04 Impact factor: 5.555